Streetbeat News

Analyst Ratings

GOOG

GOOGL

Gene Munster, a renowned tech analyst, has stated that Alphabet Inc.'s stock is poised for a significant Artificial Intelligence (AI) play over the next few years. This suggests that Alphabet's investments in AI could potentially drive its stock price higher.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:54 pm

GOOG

GOOGL

Gene Munster, a renowned analyst, has stated that Alphabet Inc. is in a strong position due to its new generative search experience. This new feature is expected to change how consumers use search engines, with Google becoming a platform for asking questions, gaining insights, and performing tasks.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:53 pm

OHI

Wells Fargo analyst Connor Siversky has maintained an Equal-Weight rating on Omega Healthcare Invts (NYSE:OHI) and raised the price target from $32 to $33.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:53 pm

EVOK

Evoke Pharma (NASDAQ:EVOK) and EVERSANA have announced that their abstract on the use of GIMOTI (nasal metoclopramide) in reducing healthcare visits for diabetic gastroparesis patients will be presented at the American Neurogastroenterology and Motility Society (ANMS) Annual Meeting. The study involved 294 patients and found that GIMOTI reduced the need for doctor's office, emergency department, inpatient, and outpatient visits. The announcement coincides with Gastroparesis Awareness Month.

Portfolio Pulse from Happy Mohamed

August 07, 2023 | 12:53 pm

AAPL

Gene Munster, a well-known technology sector analyst, has expressed a positive outlook on Apple Inc. (AAPL), stating that the company's product-service flywheel is in full swing. This suggests that Apple's strategy of creating a strong ecosystem of products and services is working effectively.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:52 pm

ABVC

ABVC BioPharma, Inc. (NASDAQ:ABVC) has published a corporate update and letter to shareholders from its CEO, Dr. Uttam Patil. The company has made significant progress in its clinical trials, including the development of a controlled-release tablet formulation for PDC-1421, a primary active ingredient in its neurological programs. The company has also completed feasibility studies for Vitargus®, a vitreous substitute for retinal detachment surgery, and has received approval to initiate the next phase of the trial in Australia. ABVC has also signed a licensing deal with Xinnovation Therapeutics Co., Ltd for the exclusive rights to develop, manufacture, market, and distribute its drugs for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder in mainland China. The deal could potentially bring in an aggregate income of $20 million for ABVC.

Portfolio Pulse from Happy Mohamed

August 07, 2023 | 12:52 pm

BPMC

JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Blueprint Medicines (NASDAQ:BPMC) and maintained a price target of $114.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 12:52 pm

AAPL

Gene Munster, a renowned analyst, has stated that the investment theme of Apple Inc. (AAPL) changes every 5-10 years. The previous theme was services, but the current theme is now the active installed base.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:51 pm

DDOG

Wedbush analyst Taz Koujalgi maintains an Outperform rating on Datadog (NASDAQ:DDOG) and raises the price target from $90 to $120.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 12:50 pm

CUBE

Wells Fargo analyst Todd Stender has maintained an Overweight rating on CubeSmart (NYSE:CUBE) but lowered the price target from $50 to $46.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:49 pm